Highly selective and sensitive hybridization-based assay for quantification of ASOs drug using signal amplification method

Scientific Resources Highly selective and sensitive hybridization-based assay for quantification of ASOs drug using signal amplification method

• Published on September 21, 2022
• Biologics & Oligonucleotides
• Drug Drug Interactions (DDI)
• Drug Metabolism
• Test Systems & Methods
• Scientific Posters

Full Title

Highly selective and sensitive hybridization-based assay for quantification of ASOs drug using signal amplification method

Authors

Yuya Ono¹, Tetsuo Sekino¹, Takuro Akiya¹, Funa Ogawa¹, Koichi Shibusawa¹, Akira Ideno¹, Masako Osawa¹, Takao Suzuki², Masaki Yamagami² and Tadashi Umemoto^2
1SEKISUI MEDICAL CO., LTD. ²Luxna Biotech Co., Ltd.

Presented at the Applied Pharmaceutical Analysis 2022 Conference

Abstract

The quantitative bioanalysis of oligonucleotide therapeutics are mainly LC-MS/MS and hybridization-based ligand binding assay (LBA).

Major advantages of LBA are simple pretreatment and high sensitivity comparing with instrumental analysis. However, the performance is not sufficient to quantify full-length ASOs in the presence of its metabolites.

Despite complex and time-consuming sample treatment, hybridization-based method usually uses enzyme (for example, S1 nuclease) to obtain selective quantification of the full length ASOs in the presence of metabolites.

We aimed to develop a novel highly selective and sensitive hybridization-based method for ASO to discriminate metabolites without enzymatic reactions to resolve the issues with LBAs.

Download Poster